ELDN - Eledon Pharmaceuticals

-

$undefined

N/A

(N/A)

Eledon Pharmaceuticals NasdaqCM:ELDN Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Location: 19800 MacArthur Boulevard, Irvine, CA, 92612, United States | Website: https://eledon.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

61.03M

Cash

124.9M

Avg Qtr Burn

-13.65M

Short % of Float

3.40%

Insider Ownership

1.40%

Institutional Own.

68.52%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tegoprubart (AT-1501) Details
Type 1 diabetes, Islet Cell Transplantation

Phase 2

Data readout

Tegoprubart (AT-1501) Details
Kidney transplantation

Phase 2

Data readout

Tegoprubart (AT-1501) Details
Amyotrophic lateral sclerosis

Phase 2

Update

Tegoprubart (AT-1501) Details
Kidney transplantation

Phase 1b

Data readout

Tegoprubart (AT-1501) Details
Autoimmune nephritis

Failed

Discontinued

Failed

Discontinued